Literature DB >> 10983986

The protooncogene TCL1 is an Akt kinase coactivator.

J Laine1, G Künstle, T Obata, M Sha, M Noguchi.   

Abstract

Human T cell prolymphocytic leukemia can result from chromosomal translocations involving 14q32.1 or Xq28 regions. The regions encode a family of protooncogenes (TCL1, MTCP1, and TCL1b) of unknown function. In yeast two-hybrid screening, we found that TCL1 interacts with Akt. All TCL1 isoforms bind to the Akt pleckstrin homology domain. Both in vitro and in vivo TCL1 increases Akt kinase activity and as a consequence enhances substrate phosphorylation. In vivo, TCL1 stabilizes the mitochondrial transmembrane potential and enhances cell proliferation and survival. In vivo, TCL1 forms trimers, which associate with Akt. TCL1 facilitates the oligomerization and activation of Akt. Our data show that TCL1 is a novel Akt kinase coactivator, which promotes Akt-induced cell survival and proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10983986     DOI: 10.1016/s1097-2765(00)00039-3

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  102 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 2.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

Review 3.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

4.  Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).

Authors:  Alexey Palamarchuk; Pearlly S Yan; Nicola Zanesi; Linan Wang; Benjamin Rodrigues; Mark Murphy; Veronica Balatti; Arianna Bottoni; Natalya Nazaryan; Hansjuerg Alder; Laura Rassenti; Thomas J Kipps; Michael Freitas; Carlo M Croce; Yuri Pekarsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

5.  TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

Authors:  Jinsheng Weng; Seema Rawal; Fuliang Chu; Hyun Jun Park; Rakesh Sharma; David A Delgado; Luis Fayad; Michelle Fanale; Jorge Romaguera; Amber Luong; Larry W Kwak; Sattva S Neelapu
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

Review 6.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

7.  Akt/PKB interacts with the histone H3 methyltransferase SETDB1 and coordinates to silence gene expression.

Authors:  Haidong Gao; Zhigang Yu; Dongsong Bi; Liyu Jiang; Yazhou Cui; Jingzhong Sun; Rong Ma
Journal:  Mol Cell Biochem       Date:  2007-06-19       Impact factor: 3.396

8.  Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages.

Authors:  Uma K Misra; Steven J Kaczowka; Salvatore V Pizzo
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

9.  1H, 15N and 13C chemical shift assignments of the Pleckstrin Homology domain of the Human Protein Kinase B (PKB/Akt).

Authors:  Daniel Auguin; Philippe Barthe; Marie-Thérèse Augé-Sénégas; François Hoh; Masayuki Noguchi; Christian Roumestand
Journal:  J Biomol NMR       Date:  2003-11       Impact factor: 2.835

10.  Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.

Authors:  Chih-Hang Anthony Tang; Sujeewa Ranatunga; Crystina L Kriss; Christopher L Cubitt; Jianguo Tao; Javier A Pinilla-Ibarz; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.